Research Article Details
| Article ID: | A24892 |
| PMID: | 22386931 |
| Source: | Metabolism |
| Title: | Serum ferritin levels predict incident non-alcoholic fatty liver disease in healthy Korean men. |
| Abstract: | Little research has been done to examine the temporal relationship between serum ferritin and the development of nonalcoholic fatty liver disease. The aim of this study was to examine whether serum ferritin levels predict incident fatty liver in non-diabetic men. The study cohort comprised 2410 healthy Korean male who were aged 30 to 59years old with no evidence of ultrasonographically detectable fatty liver (USFL) at baseline. Alcohol intake was assessed with a self-reported questionnaire. At each visit, biochemical and anthropometric measurements and abdominal ultrasonography were done. Cox proportional hazard models were used to calculate the adjusted hazard ratios in separate models for USFL. During 7545.9 person-years of follow-up, 586 participants developed USFL. The hazard ratio (95% confidence interval) for incident USFL comparing the highest quartile of serum ferritin level to the lowest quartile was 1.54 (1.21-1.94) after adjusting for age, body mass index, smoking, alcohol intake, and exercise. That association remained significant after further adjustment for cardiovascular risk factors and in time-dependent models. The association between serum ferritin and incident USFL was still significant in the non-overweight group or the no current smoker group. Serum ferritin level was an independent risk factor of incident fatty liver detected by ultrasonography even in non-obese, healthy Korean men. Increased serum ferritin levels appear to be an early predictor for incident fatty liver. |
| DOI: | 10.1016/j.metabol.2012.01.007 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D545 | Pig placenta extract | Biological extract | -- | -- | -- | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |